FARXIGA is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Dapagliflozin Propanediol.
| Product ID | 0310-6210_05eedd34-9c14-4d91-b36c-b661eff3401e | 
| NDC | 0310-6210 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | FARXIGA | 
| Generic Name | Dapagliflozin | 
| Dosage Form | Tablet, Film Coated | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2008-01-14 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA202293 | 
| Labeler Name | AstraZeneca Pharmaceuticals LP | 
| Substance Name | DAPAGLIFLOZIN PROPANEDIOL | 
| Active Ingredient Strength | 10 mg/1 | 
| Pharm Classes | Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2023-12-31 | 
| Marketing Start Date | 2015-01-05 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | NDA | 
| Application Number | NDA202293 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Marketing Start Date | 2015-01-05 | 
| Marketing Category | NDA | 
| Application Number | NDA202293 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | EA | 
| Marketing Start Date | 2015-01-05 | 
| Ingredient | Strength | 
|---|---|
| DAPAGLIFLOZIN PROPANEDIOL | 10 mg/1 | 
| SPL SET ID: | 72ad22ae-efe6-4cd6-a302-98aaee423d69 | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 0310-6205 | FARXIGA | DAPAGLIFLOZIN | 
| 0310-6210 | FARXIGA | DAPAGLIFLOZIN | 
| 50090-3481 | FARXIGA | DAPAGLIFLOZIN | 
| 50090-3482 | FARXIGA | DAPAGLIFLOZIN | 
| 55154-6932 | FARXIGA | DAPAGLIFLOZIN | 
| 55154-6933 | FARXIGA | FARXIGA | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  FARXIGA  88639033  not registered Live/Pending | AstraZeneca AB 2019-10-02 | 
|  FARXIGA  86049285  4638205 Live/Registered | Bristol-Myers Squibb Company 2013-08-27 |